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Abstract: Several lines of evidence implicate serotonergic dysfunction in diverse psychiatric disorders including anxiety, 
depression, and drug abuse. Mice with a knock-out of the 5HT1b receptor gene (HTR1B) displayed increased locomotor 
response to cocaine and elevated motivation to self-administer cocaine and alcohol. Previous genetic studies showed  
significant associations of HTR1B with alcohol dependence and substance abuse, but were followed by inconsistent re-
sults. We examined a case-control genetic association study of HTR1B with methamphetamine-dependence patients in a 
Japanese population. The subjects were 231 patients with methamphetamine dependence, 214 of whom had a co-
morbidity of methamphetamine psychosis, and 248 age- and sex-matched healthy controls. The three single nucleotide po-
lymorphisms (SNPs), rs130058 (A-165T), rs1228814 (A-700C) and rs1228814 (A+1180G) of HTR1B were genotyped. 
There was no significant difference in allelic and genotypic distributions of the SNPs between methamphetamine depend-
ence and the control. Genetic associations of HTR1B were tested with several clinical phenotypes of methamphetamine 
dependence and/or psychosis, such as age at first abuse, duration of latency from the first abuse to onset of psychosis, 
prognosis of psychosis after therapy, and complication of spontaneous relapse of psychotic state. There was, however, no 
asscocation between any SNP and the clinical phenotypes. Haplotype analyses showed the three SNPs examined were 
within linkage disequilibrium, which implied that the three SNPs covered the whole HTR1B, and distribution of estimated 
haplotype frequency was not different between the groups. The present findings may indicate that HTR1B does not play a 
major role in individual susceptibility to methamphetamine dependence or development of methamphetamine-induced 
psychosis.  
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INTRODUCTION 
  Family and twin studies have provided evidence that ge-
netic factors can influence individual differences in vulner-
ability to substance abuse and dependence [1, 2]. We previ-
ously reported that patients with methamphetamine use dis-
orders showed substantial individual differences in psy-
chotomimetic and psychotogenic effects of methampheta-
mine consumption, e.g., intensity of subjective euphoric   
effects, latency to onset of methamphetamine-induced   
psychosis, and prognosis of psychosis after discontinuance 
of methamphetamine use [3], whose clinical variations 
should be affected by individual genetic background.  
  Pharmacological manipulation of serotonergic signaling 
can modulate the activity of brain reward pathways, and thus  
 
*Address correspondence to this author at the Department of Neuropsychiatry, 
Okayama University Graduate School of Medicine, Dentistry and Pharma- 
ceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan;  
Tel: +81-86-235-7151; Fax: +81-86-235-7246;  
E-mail: hujike@cc.okayama-u.ac.jp  
the effects of substance dependence to diverse classes of 
drugs. Fluoxetine, a selective serotonin uptake inhibitor, re-
duced self-administration of cocaine [4]. Ethanol intake de-
creased after the administration of 5-HT precursors, 5-HT 
uptake inhibitors, intracerebral 5-HT, and postsynaptic 5-HT 
agonists in animals and humans [5]. These serotonergic ef-
fects against drug abuse could be mediated by 5HT1b recep-
tors at least. Administration of a 5HT1b agonist, CP-94,253, 
reduced ethanol self-administration and alcohol-induced 
aggressive behaviors via activation of postsynaptic 5HT1b 
receptors [6, 7]; in contrast, it facilitated cocaine reward   
by reducing 5HT release via 5HT1b autoreceptor stimulation 
at presynaptic sites [8]. Mice lacking 5HT1b receptors   
displayed increased locomotor response to and self-
administration of cocaine [9], and elevated alcohol consump-
tion [10].  
  Previous genetic studies indicated that the 5HT1b recep-
tor gene (HTR1B, MIM 182131) was associated with drug 
dependence and related behaviors. Thus, HTR1B polymor-
phisms were reported to be associated significantly with al-164    Current Neuropharmacology, 2011, Vol. 9, No. 1  Ujike et al. 
coholism with antisocial behaviors [11, 12], whole alcohol-
ism [13, 14], substance dependence [15] and heroin addic-
tion [16], although there were also several inconsistent re-
ports [17, 18]. Therefore, in order to investigate the roles of 
HTR1B in substance dependence, we examined a possible 
genetic association of HTR1B with methamphetamine de-
pendence in a Japanese population. 
METHODS 
Subjects 
  The subjects consisted of 231 patients with metham-
phetamine dependence (184 male, 47 female; mean age±SD, 
36.6±11.8) and 248 age-, sex-, and geographical origin-
matched healthy controls (198 male, 50 female; mean 
age±SD, 36.6±10.6), who have no individual or family his-
tory of drug dependence or major psychotic disorders such as 
schizophrenia and bipolar disorders. Almost all patients 
(N=214) are or were co-morbid with methamphetamine-
induced psychosis. All subjects were unrelated Japanese. 
Consensus diagnoses of methamphetamine dependence were 
made by two trained psychiatrists according to the ICD-10 
criteria on the basis of interviews and medical records. The 
study protocol and purpose were explained to all subjects 
participating in the study, and written informed consent was 
obtained from all subjects. This study was approved by the 
Ethics Committee of each participating institute of Japanese 
Genetics Initiative for Drug Abuse (JGIDA) [19].  
  The patients with methamphetamine dependence and/or 
psychosis were divided into subgroups according to several 
clinical phenotypes that may indicate indirectly the severity 
of and liability to dependence and psychosis: 1) age at first 
abuse of methamphetamine: younger than 20 years old, 
which is underage in Japan, or older; 2) latency to onset of 
psychotic state after initial methamphetamine consumption: 
divided into two groups by median latency of 3 years; 3) 
Duration of psychotic state after discontinuance of abuse and 
therapy with antipsychotics: transient type and prolonged 
type, which were defined as psychosis that subsides within 
one month or lasts longer than one month, respectively;   
4) complication of spontaneous psychosis after remission   
of methamphetamine-induced psychosis, and 5) multi-
substance abuse status.  
Genotyping 
 HTR1B consists of single exon and is a relatively small 
gene of about 11.7 Kb. HapMap data indicates that there is 
only one single nucleotide polymorphism (SNP) in the exon, 
rs 6297, which was proven polymorphic in a Japanese popu-
lation. However, we did not examine this SNP because it is 
synonymous, Val3Val, indicating no or less physiological 
involvement. Instead, we genotyped three SNPs flanking the 
the gene, rs6297 (A-700C) and rs130058 (A-161T) in the 5’ 
flanking region and rs1228814 (A+1180G) in the 3’ flanking 
region, which have potential to be functional. Genotyping 
was performed by the PCR-RFLP method. The genomic 
DNA was extracted from peripheral leukocytes using a stan-
dard method. Each polymorphic site was amplified by PCR 
(the PCR primer sequence of each SNP is available on re-
quest) in a 15-ml volume containing 3% dimethyl sulfoxide 
and 0.75 units of Taq DNA polymerase (Promega Co., Japan) 
using a unique primer set. The PCR reaction was performed 
under the following conditions: 95°C for 5 min, then 35   
cycles of 30 s of denaturing at 95°C, 1 min of annealing at 
the appropriate temperature, and 30 s of extension, and final 
elongation at 72°C for 10 min. The PCR products were   
digested with the corresponding restriction enzyme for each 
polymorphism, NdeI for rs6297, NlaIII for rs130058 and 
Cfro13I for rs1228814, and then electrophoresed on 3.0% 
agarose gels and stained with GelStar (Takara Co., Japan). 
All genotyping was performed in a blinded fashion, with the 
control and cases samples mixed randomly. The genotyping 
of the SNPs were confirmed in part by direct sequencing.  
Statistical Analysis 
  Statistical analysis of association was performed using 
SNPAlyze software (Dynacom Co., Japan). Deviation from 
Hardy-Weinberg equilibrium and the case-control study 
were tested using the 
2 test for goodness of fit and 
2 test 
for dependence, respectively. Linkage disequilibrium (LD) 
was tested using the 
 2 test, and D’ and r
2 values were made 
the index in the authorization of LD. Case-control haplotype 
analysis was performed by the permutation method, and 
permutation p-values were calculated based on 100,000 rep-
lications.  
RESULTS 
  The genotype distribution and allele frequencies of the 
each polymorphism are shown in Table 1. The genotype dis-
tributions of patients and control subjects did not deviate 
from Hardy-Weinberg equilibrium at any SNP examined. 
We found no significant difference between the patients and 
controls in the frequencies of the genotype or allele at any 
SNP of HTR1B (rs6297: allele: p=0.37, genotype: p=0.38, 
rs130058: allele: p=0.30, genotype: p=0.33 rs1228814: al-
lele: p=0.14, genotype: p=0.47).  
  We estimated the pairwise LD between the three SNPs of 
HTR1B using the D’ and r
2 values as an index. A D’ of more 
than 0.7 was found between all the SNPs (0.8455 between 
rs6297 and rs130058, 1.000 between rs6297 and rs1228814, 
0.8216 between rs130058 and rs1228814) indicating that the 
three SNPs are in linkage disequilibrium (LD) and located 
within one LD block. Then, we performed case-control 
haplotype analysis (Table 2). There were 5 kinds of haplo-
types consisting of the three SNPs. There was no significant 
difference in distribution of haplotype between metham-
phetamine dependence and controls (overall permutation 
p=0.81). Neither haplotype consisting of the two SNPs in the 
promoter region (rs6297 and rs130058) showed a significant 
difference in distribution between the groups. 
  Additional analyses of subgroups of patients with meth-
amphetamine dependence/psychosis stratified by five items 
of clinical phenotypes (Table 3) revealed that there was no 
significant association of any SNP of HTR1B with any clini-
cal phenotype of methamphetamine dependence and/or psy-
chosis. 
DISCUSSION 
  The 5HT1b receptors are expressed in the brain of ro-
dents, and homologous 5HT1D receptors are expressed in 
the human brain. The 5HT1b receptors are located at nerve 5HT1b Receptor and Methamphetamine Dependence  Current Neuropharmacology, 2011, Vol. 9, No. 1    165 
terminals of various pathways and act as autoreceptors that 
are involved in the regulation of release of diverse neuro-
transmitters, including serotonin itself [20]. The 5HT1b re-
ceptors are also located at postsynaptic sites. A lot of studies 
suggest that 5HT1b receptors are implicated in several 
physiological functions, behaviors, and neuropsychiatric 
disorders including migraine, aggression, anxiety, depres-
sion, and substance dependence [20].  
  Genetic associations of HTR1B have been examined with 
various psychiatric conditions such as antisocial behaviors, 
suicide, depression, and schizophrenia. As to substance de-
pendence, Lappapleinene et al. [11] found that rs6296, a 
synonymous SNP in exon 1 (G861C, Val3Val), was associ-
ated with antisocial alcoholism in two independent popula-
tions of alcoholic patients for the first time, but this was fol-
lowed by consistent [12] and inconsistent results [15, 17, 18, 
21]. Finally, Fehr et al. [13] reported that the risk allele of 
861C reported by Lappapleinene et al. [11] was protective in 
their patients with alcoholism. These inconsistencies among 
alcoholism studies may indicate that status of co-morbidity 
with other substance abuse could influence the results be-
cause  HTR1B was shown to be associated with substance 
abuse [15] and heroin addiction [16].  
  In the present study, we examined three SNPs in the 5’ 
and 3’ flanking regions of HTR1B, rs6297 (A-700C), 
rs130058 (A-161T), and rs1228814 (A+1180G) in patients 
with methamphetamine dependence and found no associa-
tion at any loci. Neither was any association found with sev-
eral clinical phenotypes, such as initial abuse of metham-
phetamine at a younger age, rapid onset of psychotic state 
induced by methamphetamine, longer duration of psychosis 
after discontinuance of methamphetamine abuse, complica-
tion of spontaneous relapse of psychosis after remission, and 
multi-substance abuse status. Haplotype analysis of the three 
SNPs also showed no significant difference in haplotype 
distribution between the patients and controls. As the LD 
block consisting of the three SNPs covers the whole of 
HTR1B, it is unlikely that any untested polymorphism in-
cluding G861C in HTR1B could be associated with metham-
phetamine dependence or its clinical phenotypes. Our find-
ings are consisted with a study of cocaine, another psy-
chostimulant, which showed that T-261G, A-161T, and 
G861C of HTR1B was not associated with cocaine abuse 
[17]. 
 Duan  et al. [22] examined effects of common SNPs in 
the promoter region of HTR1B on its transcription activity by 
in vitro reporter assay and revealed that T-261G and A-161T 
(rs130058) potently affected gene expression. The haplo-
types consisting of -261G and -161A enhanced transcrip-
tional activity 2.3-fold compared with major haplotype con-
sisting of -261T and -161T. The A-161T polymorphism al-
tered characteristics of binding to AP-1 transcription factor. 
Table 1.  Case-Control Association Analyses of HTR1B 
Loci    Groups  N   Genotype (%)   p  Allele (%)   p 
SNP1 (rs6297)   A/A  A/G  G/G    A  G   
Control  248  73.4  23.8  2.8    85.3  14.7   
MAP-dependence  228  68.9  27.6  3.5  0.37  82.7  17.3  0.38 
SNP2 (rs130058)     T/T  T/A  A/A    T  A   
Control  227  87.2  12.8  0    93.6  6.4   
MAP-dependence  229  89.5  10.5  0  0.3  94.8  5.2  0.33 
SNP3 (rs1228814)     C/C  C/A  A/A    C  A   
Control  246  73.6  25.2  1.2    86.2  13.8   
MAP-dependence  225  70.7  27.5  1.8  0.14  84.4  15.6  0.47 
 
Table 2.  Haplotype Analysis of HTR1B in Methamphetamine Dependence 
Haplotype Controls  MAP-Dependence p 
A-T-C 0.6973 0.6721  0.41 
G-T-C 0.1480 0.1673  0.43 
A-T-A 0.0902 0.1095  0.33 
A-A-A 0.0520 0.0461  0.68 
A-A-C 0.0094 0.0034  0.26 
Global permutation p value =0.81 (c
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Table 3.  Association of HTR1B with Clinical Phenotypes of Methamphetamine Dependence and Psychosis 
SNP1 (rs6297)  N   Genotype (%)   p  Allele (%)   p 
  A/A  A/G  G/G    A  G   
Age at first use                 
20y <=  111  0.68  0.26  0.05    0.82  0.18   
19y >=  113  0.68  0.30  0.02  0.37  0.83  0.17  0.38 
Latency of psychosis 
3y >  103  0.64  0.31  0.05    0.80  0.20   
3y <=  83  0.70  0.28  0.02  0.57  0.84  0.16  0.31 
Prognosis of psychosis 
Transient  114  0.68  0.30  0.03    0.82  0.18   
Prolonged  84  0.69  0.26  0.05  0.65  0.82  0.36  0.94 
Spontaneous relapse of psychotic symptoms  
＋  84  0.62  0.36  0.02    0.80  0.20   
－  129  0.71  0.24  0.05  0.15  0.83  0.17  0.35 
Poly-substance abuse 
＋  158  0.69  0.28  0.03    0.83  0.17   
－  63  0.68  0.27  0.05  0.85  0.82  0.18  0.77 
SNP2 (rs130058)  N   Genotype (%)   p  Allele (%)   p 
   T/T  T/A  A/A    T  A   
Age at first use 
20y <=  111  0.86  0.14  0.00    0.93  0.07   
19y >=  114  0.92  0.08  0.00  0.31  0.96  0.04  0.33 
Latency of psychosis 
3y >  103  0.91  0.09  0.00    0.96  0.04   
3y <=  84  0.90  0.10  0.00  0.85  0.95  0.05  0.86 
Prognosis of psychosis 
Transient  115  0.88  0.12  0.00    0.94  0.06   
Prolonged  84  0.93  0.07  0.00  0.24  0.96  0.04  0.26 
Spontaneous relapse of psychotic symptoms  
＋  85  0.92  0.08  0.00    0.96  0.04   
－  129  0.87  0.13  0.00  0.26  0.93  0.07  0.28 
Poly-substance abuse 
＋  159  0.90  0.10  0.00    0.95  0.05   
－  63  0.87  0.13  0.00  0.57  0.94  0.06  0.58 5HT1b Receptor and Methamphetamine Dependence  Current Neuropharmacology, 2011, Vol. 9, No. 1    167 
Table 3. contd…. 
SNP3 (rs1228814)  N   Genotype (%)   p  Allele (%)   p 
   C/C  C/A  A/A    C  A   
Age at first use                 
20y <=  110  0.72  0.25  0.04    0.84  0.16   
19y >=  111  0.68  0.32  0.00  0.14  0.84  0.16  0.47 
Latency of psychosis 
3y >  100  0.76  0.22  0.02    0.87  0.13   
3y <=  83  0.66  0.33  0.01  0.27  0.83  0.17  0.23 
Prognosis of psychosis 
Transient  113  0.71  0.28  0.01    0.85  0.15   
Prolonged  82  0.73  0.24  0.02  0.59  0.85  0.15  0.91 
Spontaneous relapse of psychotic symptoms  
＋  81  0.73  0.27  0.00    0.86  0.14   
－  129  0.69  0.28  0.03  0.27  0.83  0.17  0.34 
Poly-substance abuse 
＋  156  0.70  0.28  0.02    0.84  0.16   
－  62  0.69  0.29  0.02  0.98  0.84  0.16  0.98 
 
Therefore, our negative findings may be significant and indi-
cate that higher or lower density of the 5HT1b receptor due 
possession of -161A or -161T of HTR1B does not affect in-
dividual susceptibility to methamphetamine dependence and 
psychosis.  
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